Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 2, 2007, Pages 564-566

  Otsuka, Tatsui ^a   Togo, Takashi ^a   Sugiyama, Naoya ^a   Uehara, Kumi ^a   Yoshimi, Asuka ^a   Karashima, Aya ^a   Shioya, Hiromi ^a   Hirayasu, Yoshio ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Augmentation therapy; Depression; Obsessive compulsive disorder; Perospirone

Indexed keywords

AMOXAPINE; CLOMIPRAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUVOXAMINE; LITHIUM CARBONATE; MIANSERIN; MILNACIPRAN; PAROXETINE; PEROSPIRONE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SULPIRIDE;

ADULT; ARTICLE; CASE REPORT; DEPRESSION; DIAGNOSTIC VALUE; DISEASE COURSE; DOPAMINE RELEASE; FEMALE; HUMAN; MAJOR DEPRESSION; OBSESSIVE COMPULSIVE DISORDER; SEROTONIN RELEASE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DEPRESSION; DRUG SYNERGISM; FEMALE; HUMANS; INDOLES; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; THIAZOLES;

EID: 33846840714     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.10.014     Document Type: Article

References (24)

1. Appelberg B.G., Syvalahti E.K., Koskinen T.E., Mehtonen O.P., Muhonen T.T., and Naukkarinen H.H. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 62 (2001) 448-452
2. Araneda R., and Andrade R. 5-Hydroxytryptamine2 and 5-hydroxytryptamine 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40 (1991) 399-412
3. Ashby Jr. C.R., Edwards E., and Wang R.Y. Electrophysiological evidence for a functional interaction between 5-HT1A and 5-HT2A receptors in the rat medial prefrontal cortex: an iontophoretic study. Synapse 17 (1994) 173-181
4. Barbee J.G., Conrad E.J., and Jamhour N.J. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 65 (2004) 975-981
5. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., Coric V., Bracken M.B., and Leckman J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11 (2006) 622-632
6. Chen Y.W., and Dilsaver S.C. Comorbidity for obsessive-compulsive disorder in bipolar and unipolar disorders. Psychiatry Res 59 (1995) 57-64
7. Connor K.M., Payne V.M., Gadde K.M., Zhang W., and Davidson J.R. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 66 (2005) 49-51
8. D'Amico G., Cedro C., Muscatello M.R., Pandolfo G., Di Rosa A.E., Zoccali R., et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 619-623
9. de Paulis T. Perospirone (Sumitomo Pharmaceuticals). Curr Opin Investig Drugs 3 (2002) 121-129
10. Eddy K.T., Dutra L., Bradley R., and Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24 (2004) 1011-1030
11. Fineberg N.A., and Gale T.M. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol 8 (2005) 107-129
12. Goodman W.K., McDougle C.J., Price L.H., Riddle M.A., Pauls D.L., and Leckman J.F. Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder?. J Clin Psychiatry 51 (1990) 36-43 [Suppl]
13. Grady T.A., Pigott T.A., L'Heureux F., Hill J.L., Bernstein S.E., and Murphy D.L. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 150 (1993) 819-821
14. Karno M., Golding J.M., Sorenson S.B., and Burnam M.A. The epidemiology of obsessive compulsive disorder in 5 US communities. Arch Gen Psychiatry 45 (1988) 1094-1099
15. Keuneman R.J., Pokos V., Weerasundera R., and Castle D.J. Antipsychotic treatment in obsessive-compulsive disorder: a literature review. Aust N Z J Psychiatry 39 (2005) 336-343
16. Lakoski J.M., and Aghajanian G.K. Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 24 (1985) 265-273
17. Leysen J.E., Janssen P.M., Megens A.A., and Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55 (1994) 5-12 [Suppl]
18. Li X., May R.S., Tolbert L.C., Jackson W.T., Flournoy J.M., and Baxter L.R. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 66 (2005) 736-743
19. Matsushita M., Egashira N., Harada S., Okuno R., Mishima K., Iwasaki K., et al. Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT(1A) receptor in mice: implications for obsessive-compulsive disorder. J Pharmacol Sci 99 (2005) 154-159
20. McDougle C.J., Goodman W.K., Leckman J.F., Holzer J.C., Barr L.C., McCance-Katz E., et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 150 (1993) 647-649
21. Overstreet D.H., Commissaris R.C., De La Garza II R., File S.E., Knapp D.J., and Seiden L.S. Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models. Stress 6 (2003) 101-110
22. Papakostas G.I., Petersen T.J., Kinrys G., Burns A.M., Worthington J.J., Alpert J.E., et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66 (2005) 1326-1330
23. Pato M.T., Pigott T.A., Hill J.L., Grover G.N., Bernstein S., and Murphy D.L. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 148 (1991) 127-129
24. Rickels K., Schweizer E., Clary C., Fox I., and Weise C. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 164 (1994) 802-805